• Immunovant to Present at the 11th Annual SVB Leerink Global Healthcare Conference

    Source: Nasdaq GlobeNewswire / 09 Feb 2022 07:00:01   America/Chicago

    NEW YORK, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference, taking place February 14 - 18, 2022.

    11th Annual SVB Leerink Global Healthcare Conference
        
    Date:  Wednesday, February 16th, 2022
        
    Time:  11:20am Eastern Time
        
    Webcast:  The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com

    About Immunovant, Inc. 

    Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Immunovant is developing batoclimab, formerly referred to as IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies. 

    Contact:

    Tom Dorney, MS, MBA
    Director, Investor Relations & Strategy
    Immunovant, Inc.
    info@immunovant.com


    Primary Logo

Share on,